Nakagomi K, Yokota I, Ajisaka K
Meiji Institute of Health Science, Meiji Milk Products Co., Ltd., Odawara, Japan.
Thromb Res. 1991 Jul 1;63(1):111-21. doi: 10.1016/0049-3848(91)90274-z.
An innovative chemically modified thrombin, succinylthrombin, was prepared by the treatment of thrombin with succinic anhydride. Succinylthrombin showed a remarkable reduction of fibrinogen clotting activity with a reduction of the potency for protein C (PC) activation. However, the degree of the remaining potency for PC activation was greater than the degree of the remaining clotting activity. The potency for PC activation was enhanced by the addition of thrombomodulin and calcium ion. The degree of the enhancement was approximately 6-times greater than that of acetylthrombin, which we previously suggested as an effective anticoagulant. The infusion of succinylthrombin into rabbits induced a prolongation of the activated partial thromboplastin time (APTT). The fibrinogen level was not affected even by the infusion of succinylthrombin of a dose which cause the prolongation of the APTT to the same extent as that following an infusion of thrombin. The factor Xa clotting time was also prolonged by the succinylthrombin without any significant drop in the number of the circulating platelet.
一种创新的化学修饰凝血酶——琥珀酰凝血酶,是通过用琥珀酸酐处理凝血酶而制备的。琥珀酰凝血酶显示出纤维蛋白原凝血活性显著降低,同时蛋白C(PC)激活能力也降低。然而,剩余的PC激活能力程度大于剩余的凝血活性程度。通过添加血栓调节蛋白和钙离子,PC激活能力得到增强。增强程度比我们之前提出的有效抗凝剂乙酰凝血酶大约大6倍。向兔子输注琥珀酰凝血酶会导致活化部分凝血活酶时间(APTT)延长。即使输注能使APTT延长至与输注凝血酶后相同程度的剂量的琥珀酰凝血酶,纤维蛋白原水平也不受影响。琥珀酰凝血酶还会延长因子Xa凝血时间,而循环血小板数量没有明显下降。